| Дата: Вторник, 30.12.2014, 00:33 | Сообщение # 1 |
|
Tamoxifen is an foe of the estrogen receptor in knocker series via its active metabolite, hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and thus may be characterized as a confused agonist/antagonist. Tamoxifen is the everyday endocrine (anti-estrogen) analysis in place of hormone receptor-positive breast cancer in pre-menopausal women, and is also a stock in post-menopausal women although aromatase inhibitors are also oftentimes used in that setting.[1 -
Some titty cancer cells call for estrogen to grow. Estrogen binds to and activates the estrogen receptor in these cells. Tamoxifen is metabolized into compounds that also fix to the estrogen receptor but do not initiate it. Because of this competitive hostility, tamoxifen acts like a level in disrepair misled in the keep track of exclude that prevents any other cue from being inserted, preventing estrogen from binding to its receptor. Thus bosom cancer cell spread is blocked.
Tamoxifen was discovered during pharmaceutical company Sovereign Chemical Industries[2 - (on occasion AstraZeneca) and is sold under the barter names Nolvadex, Istubal, and Valodex. However, the drug, monotonous prior to its patent coming to an end, was and still is extremely referred to nigh its generic term "tamoxifen."
Medical uses
Core cancer
Tamoxifen is currently used for the treatment of both early and advanced ER+ (estrogen receptor outright) breast cancer in pre- and post-menopausal women.[3 - Additionally, it is the most worn out hormone treatment for virile core cancer.[4 - It is also approved by the FDA quest of the restraining of breast cancer in women at extreme imperil of developing the disease.[5 - It has been too approved in the direction of the reduction of contralateral (in the conflicting bosom) cancer.
In 2006, the large STAR clinical consider concluded that raloxifene is equally noticeable in reducing the incidence of core cancer, but after an for the most part 4-year backup there were 36% fewer uterine cancers and 29% fewer blood clots in women engaging raloxifene than in women taking tamoxifen, although the contradistinction is not statistically significant.[6 - [7 - [8 -
In 2005, the ATAC stab showed that after general 68 months following a 5 year adjuvant treatment, the set that receivedanastrozole (Arimidex) had significantly more wisely results than the tamoxifen troupe in measures like condition unconstrained survival, but no complete mortality benefit.[9 - Statistics from the trying out suggest that anastrozole should be the preferred medication for postmenopausal women with localized breast cancer that is estrogen receptor (ER) positive.[10 - Another deliberate over develop that the imperil of recurrence was reduced 40% (with some risk of bone cleavage) and that ER adversary patients also benefited from switching to anastrozole.[11 - [12 -
From http://www.fmyykj.com - suzhou pharmaceutical technology co.,ltd.
|
| |
|
|
